The panel / Androgens

Estradiol, sensitive assay

Estradiol is the most over-managed number in men's health, and the confusion comes from collapsing two separate questions. Should it be measured, and should it be suppressed. We measure it on every patient. We do not routinely suppress it, and the evidence on that second point is not close.

What it measures

Estradiol is the main oestrogen, and men make it by converting testosterone through an enzyme called aromatase. It is not a contaminant of male physiology. It carries a share of the benefit that testosterone gets credit for, particularly for bone density and sexual desire.

Made by converting testosterone, mostly in fat tissue

Circulates in men at very low levels, typically under 30 to 40 pg/mL

Required for bone density, and linked to sexual desire

In an analysis of the Testosterone Trials, the change in estradiol was the single best predictor of gains in bone density and sexual desire. That is the opposite of how it is usually discussed, and it is the main reason we want the baseline rather than treating estradiol as something to drive down.

How it is measured

SpecimenSerum

TimingWith the morning testosterone draw

AssaySensitive LC-MS/MS where a number will drive a decision

AvoidStandard direct immunoassay in men

ConversionRoughly 3.67 pmol/L per pg/mL

TurnaroundTypically 3 to 5 days

The assay problem is not a technicality. Men run estradiol at concentrations below the range where ordinary automated immunoassays are valid. Compared head to head against mass spectrometry in men over 40, five commercial direct assays overstated the result by between 6 and 74 percent, and two of them could only detect estradiol in about half to three quarters of samples at all. Only the mass spectrometry values tracked properly with testosterone and SHBG. If a decision rests on the number, it needs the sensitive assay.

Why it is on the panel

We draw it on every patient at the first visit. That is a deliberate practice choice and worth being straight about: current AUA guidance recommends measuring estradiol specifically in men with breast symptoms or gynecomastia rather than universally. Our reasoning is that a first visit is the one opportunity to establish a complete baseline, that estradiol interacts with almost everything else on this panel, and that having the starting value makes any later change interpretable instead of alarming. It is included in the visit, so it costs you nothing to have it.

Interpretation

Reading the result

Reference values are method-dependent, so a result is only interpretable alongside the assay that produced it. Mass spectrometry studies in healthy men cluster around the mid-20s in pg/mL.

Bands used in practice

Under roughly 40 pg/mLThe usual male range. Recorded as your baseline, no action indicated.

Above 40 pg/mL at baselineAUA suggests endocrinology referral before starting therapy.

Raised on therapy, no symptomsExpected, and monitored rather than treated.

Raised with breast tenderness or tissueThe situation that changes management. Assessed clinically, since symptoms often settle.

A high estradiol is not the cause of low testosterone, despite how often that is claimed. And there is no evidence that treating an asymptomatic raised estradiol during testosterone therapy improves anything. Measuring a number and acting on a number are different decisions, and we keep them separate.

What raises estradiol in men

Most of what raises it is either expected on therapy or a reason to address something else.

5 things that move it

Testosterone itself. More substrate means more conversion, so a rise on therapy is normal.

Body fat. Aromatase lives in adipose tissue, so higher fat mass means more conversion.

Age. The ratio of oestrogen to testosterone rises with age even when the absolute level moves little.

Alcohol and liver disease, both of which impair clearance.

Rarely, an oestrogen-secreting tumour, which is worth considering only when the level is strikingly high.

What happens next

A normal baseline is recorded and carried forward, so that a later change can be read against your own starting point rather than a population range.

A raised result from a standard immunoassay is repeated on a sensitive assay before it is believed.

Breast tenderness or new breast tissue is examined, and the timeline matters, because tissue present over a year is unlikely to regress with any medical treatment.

A baseline above 40 pg/mL, or a strikingly high result, prompts endocrinology referral rather than a prescription to suppress it.

Straight answers

Not routinely, and we will explain why rather than just refuse. There is no evidence base for prophylactic aromatase inhibitor use during testosterone therapy, and there is evidence of harm: in a year-long randomised trial in older men, anastrozole raised testosterone and lowered estradiol while reducing spine bone density compared with placebo. Guidance also warns against extended use for exactly that reason. Estrogen blockers have real indications in men. Routine suppression of a normal number is not one of them.